Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961100 | 0.88 | NPC1 (0.39) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL1773521 | 0.86 | FYN (0.39) | AGTR1AGTR2 | |
| SCHEMBL6953051 | 0.85 | HSD11B1 (0.47) | TP53AGTR1AGTR2 | |
| SCHEMBL29366164 | 0.84 | TRPA1 (0.35) | AGTR1AGTR2 | |
| SCHEMBL1132111 | 0.84 | TAAR1 (0.43) | TP53 | |
| SCHEMBL21034528 | 0.84 | DCUN1D1 (0.33) | AGTR1AGTR2 | |
| SCHEMBL6962635 | 0.84 | AKT1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL3376281 | 0.84 | TRPA1 (0.35) | AGTR1AGTR2 | |
| SCHEMBL15908141 | 0.84 | BRS3 (0.36) | AGTR1AGTR2 | |
| SCHEMBL6960829 | 0.84 | BRD4 (0.39) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021182898-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | 애니젠 주식회사 | 2021-09-16 | — | — | WO | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2020027304-A1 | NOVEL CAROTENOID-RELATED DERIVATIVES, AND SALTS, ESTERS, OR AMIDES THEREOF | アスタファーマシューティカルズ株式会社 | 2020-02-06 | — | — | WO | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9828343-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9725441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170158681-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611221-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2116548-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | Novartis AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2005014602-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-0711762-B1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| WO-1993013100-A1 | METHOD FOR PRODUCING BIS-PYRIDINIC DERIVATIVES WITH ACETYLCHOLINESTERASE INHIBITING PROPERTIES | BOEHRINGER INGELHEIM ESPAÑA S.A. (ES) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | ABL1, TBCA, TBC1D5 | TP53 3193/4885PDE4A 4812/4885PDE4B 4559/4885 |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | TP53 365/4885PDE4A 286/4885PDE4B 346/4885 |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | TP53 365/4885PDE4A 286/4885PDE4B 346/4885 |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | TP53 365/4885PDE4A 286/4885PDE4B 346/4885 |
| US-20170158681-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | TP53 365/4885PDE4A 286/4885PDE4B 346/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | TP53 365/4885PDE4A 286/4885PDE4B 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.